Lars Blumenstein

机构：Novartis (Switzerland), Novartis Institutes for BioMedical Research · ORCID：0009-0004-6018-8049

发表论文 82 篇 · 总被引 1851 次 · h-index 20

代表论文

• Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (2018 · Journal of Clinical Oncology · 被引 455)
• Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer (2018 · JAMA Oncology · 被引 261)
• Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy (2023 · Journal of Nuclear Medicine · 被引 70)
• Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption (2021 · Journal of Pharmaceutical Sciences · 被引 54)
• Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers (2015 · Cancer Chemotherapy and Pharmacology · 被引 43)
• Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study (2021 · European Journal of Cancer · 被引 27)